Effectiveness of radiotherapy for head and neck skin cancers: a single-institution study
- Author:
Jae Wang KIM
1
;
Byung Min YUN
;
Myoung Soo SHIN
;
Jae Kyoung KANG
;
JungJu KIM
;
Young Suk KIM
Author Information
- Publication Type:Original Article
- Keywords: Skin cancer; Radiotherapy; Treatment outcome; Toxicity
- MeSH: Asian Continental Ancestry Group; Carcinoma, Squamous Cell; Follow-Up Studies; Head; Humans; Lymph Nodes; Neck; Neoplasm Metastasis; Radiotherapy; Retrospective Studies; Skin Neoplasms; Skin; Treatment Outcome
- From:Radiation Oncology Journal 2019;37(4):293-301
- CountryRepublic of Korea
- Abstract: PURPOSE: External beam radiotherapy (EBRT) is a useful option to treat head and neck skin cancer patients who are not indicated for surgery. In this study, we evaluated the treatment outcomes of EBRT in an Asian population.MATERIALS AND METHODS: The records from 19 head and neck skin cancer patients (10 with squamous cell carcinoma and 9 with basal cell carcinoma) who were treated with definitive or adjuvant EBRT from 2009 to 2017 were retrospectively reviewed. The radiotherapy doses administered ranged from 50 to 66 Gy (median, 55 Gy) with 2.0–2.75 Gy per daily fraction (median, 2.5 Gy). The T stage at presentation was as follows: Tis (1 patient), T1 (11 patients), T2 (6 patients), and T3 (1 patient). None had regional lymph node disease or distant metastasis at presentation. The local failure-free survival (LFFS) rates, toxicity, and cosmetic results were analyzed.RESULTS: The median age was 75.5 years (range, 52.6 to 92.5 years). The median follow-up duration from the completion of radiotherapy was 44.9 months (range, 5.8 to 82.6 months). One local failure occurred in a patient with a 2.1-cm posterior neck squamous cell carcinoma at 32.5 months after radiotherapy (1/19, 5.3%). The 3-year LFFS rate was 91.7%. No patients died from skin cancer during follow-up, and no grade 3 complications occurred. The cosmetic outcomes were excellent for 16 (84.2%) and good for 3 (15.8%) of the 19 patients.CONCLUSION: EBRT offers good local control and cosmetic outcomes in patients with head and neck skin cancer, with no grade 3 complications.
